Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 06, 2025 | May 08, 2025 |
| ORACLE CORPORCL · Entity 2805 | Director | September 29, 2026 | October 02, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | March 06, 2023 | March 08, 2023 |
| TENET HEALTHCARE CORPTHC · Entity 2563 | Director | May 22, 2025 | May 28, 2025 |
| XEROX CORPXRX · Entity 12016 | Director | January 12, 2018 | January 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date May 06, 2025 · Filed May 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 16,499 |
Reported balance
After 2025-05-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-06 · Grant · Acquired 7,183 · Balance 16,499 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2: Total includes the automatic reinvestment of dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
F2: Total includes the automatic reinvestment of dividends.
ORACLE CORP
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Stephen H. Rusckowski Living Trust | 25,390 |
Reported balance
After 2026-09-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-29 · Purchase · Acquired 25,000 · Balance 25,390 F1: This transaction was executed in multiple trades at prices ranging from $138.96 to $139.74. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 60 |
Reported balance
Holding disclosure · report date 2026-09-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 60 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $138.96 to $139.74. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
QUEST DIAGNOSTICS INC
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 389,597 |
Last balance in matching sequence
After 2023-03-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-03-06 · Grant · Acquired 82,631 · Balance 428,201 F1: Represents an award of restricted share units granted on February 25, 2013. F2: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). Row 2 · 2023-03-06 · Tax withholding · Disposed 38,604 · Balance 389,597 F1: Represents an award of restricted share units granted on February 25, 2013. F3: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units granted on February 25, 2013.
F2: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d).
F3: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.
TENET HEALTHCARE CORP
Report date May 22, 2025 · Filed May 28, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,233 |
Reported balance
After 2025-05-23 transaction · row 1
1 source rowRow 1 · 2025-05-23 · Exercise / conversion · Acquired 1,551 · Balance 5,233 F1: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-05-22 | Direct | 1,333 |
Reported balance
After 2025-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-22 · Grant · Acquired 1,333 · Balance 1,333 F2: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2025-05-23 | Direct | 0 |
Reported balance
After 2025-05-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-23 · Exercise / conversion · Disposed 1,551 · Balance 0 F1: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock.
F2: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares.
XEROX CORP
Report date January 12, 2018 · Filed January 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table I · non-derivative | Direct | 17,952 |
Reported balance
After 2018-01-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-01-12 · Grant · Acquired 2,793 · Balance 17,952 F1: Each DSU represent the right to receive one share of common stock upon the reporting person's termination of service as a director. F2: This amount includes 103 shares paid on 7/31/17 and 113 shares paid on 10/31/17 from the reinvestment of dividend equivalents paid on Deferred Stock Units held as of 6/30/2017 and 9/29/2017, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Each DSU represent the right to receive one share of common stock upon the reporting person's termination of service as a director.
F2: This amount includes 103 shares paid on 7/31/17 and 113 shares paid on 10/31/17 from the reinvestment of dividend equivalents paid on Deferred Stock Units held as of 6/30/2017 and 9/29/2017, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2026 Filed Oct 2, 2026 01:42 UTC | ORACLE CORP ORCL · Entity 2805 | PurchaseCommon Stock | 25,000 | $139.35 | $3,483,800.00 |
DisclosureSEC source: 0001341439-26-000099 · form4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Stephen H. Rusckowski Living Trust Disclosed balance after: 25,390 F1 · price: This transaction was executed in multiple trades at prices ranging from $138.96 to $139.74. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2026 Filed Jun 2, 2026 21:48 UTC | ORACLE CORP ORCL · Entity 2805 | GrantRestricted Stock Unit · Derivative | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001341439-26-000054 · form4.xml · derivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550 Underlying: Common Stock · 1,550 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest 100% on first anniversary of grant date. F2 · derivative.expiration_date: Restricted stock units vest 100% on first anniversary of grant date. Read SEC document |
| November 18, 2025 Filed Nov 21, 2025 01:34 UTC | ORACLE CORP ORCL · Entity 2805 | GrantRestricted Stock Unit · Derivative | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001341439-25-000078 · form4.xml · derivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 793 Underlying: Common Stock · 793 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest 100% on first anniversary of grant date. F2 · derivative.expiration_date: Restricted stock units vest 100% on first anniversary of grant date. Read SEC document |
| May 23, 2025 Filed May 28, 2025 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Exercise / conversionRestricted Stock Units · Derivative | 1,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-078022 · ownership.xml · derivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,551 shares Expires 2025-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. F1 · price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. Read SEC document |
| May 23, 2025 Filed May 28, 2025 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | Exercise / conversionCommon Stock | 1,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-078022 · ownership.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of Tenet Healthcare Corp (THC) common stock. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-078022 · ownership.xml · derivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2026-05-22 F2 · derivative.exercise_price: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. Read SEC document |
| May 06, 2025 Filed May 8, 2025 20:27 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 7,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-008901 · form4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,499 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:00 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantRestricted Stock Units · Derivative | 1,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-065549 · ownership.xml · derivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,551 Underlying: Common Stock · 1,551 shares Expires 2025-05-23 F1 · derivative.exercise_price: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. These restricted stock units vest on the first anniversary of the date of grant. The reporting person may elect to receive up to 37% of these restricted stock units in cash in lieu of shares. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:34 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 5,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009783 · form4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,068 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:03 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 3,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017016 · form4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,049 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| May 26, 2023 Filed May 30, 2023 21:41 UTC | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 2,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032958 · doc4.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,846 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). Read SEC document |
| May 26, 2023 Filed Jun 23, 2023 23:43 UTC Amendment | TENET HEALTHCARE CORP THC · Entity 2563 | GrantCommon Stock | 3,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039557 · doc4a.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,682 F1 · security: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F1 · shares: Represents restricted stock units granted under the Company's Stock Incentive Plan. Each restricted stock unit is the economic equivalent of one share of the Company's common stock. All of these restricted stock units vested immediately on the grant date and will be settled in shares of common stock on the third anniversary of the date of grant (unless deferred settlement has been elected). F2 · shares: This amendment is being filed to correct the amount of restricted stock units granted on May 26, 2023. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 38,604 | $147.86 | $5,707,987.44 |
DisclosureSEC source: 0001022079-23-000064 · wf-form4_167831097116995.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,597 F1 · security: Represents an award of restricted share units granted on February 25, 2013. F3 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 82,631 | $147.86 | $12,217,819.66 |
DisclosureSEC source: 0001022079-23-000064 · wf-form4_167831097116995.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,201 F1 · security: Represents an award of restricted share units granted on February 25, 2013. F2 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:56 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,496 | $140.69 | $491,852.24 |
DisclosureSEC source: 0001022079-23-000052 · wf-form4_167788053093571.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,570 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:54 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 20,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000037 · wf-form4_167753483583104.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,066 F2 · security: Represents an award of restricted share units granted on February 25, 2013. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:54 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 5,826 | $147.86 | $861,432.36 |
DisclosureSEC source: 0001022079-23-000037 · wf-form4_167753483583104.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,007 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 14,854 | $86.63 Strike: $86.63 | $1,286,802.02 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · derivative · entry 10 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,854 shares Expires 2029-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F9 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 10,037 | $103.57 Strike: $103.57 | $1,039,532.09 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · derivative · entry 9 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,037 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F8 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 900 | $142.13 | $127,920.60 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 8 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,833 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F7 · price: This transaction was executed in multiple trades at prices ranging from $142.06 to $142.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 4,131 | $141.35 | $583,908.59 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 7 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,733 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F6 · price: This transaction was executed in multiple trades at prices ranging from $141.02 to $141.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 9,823 | $140.58 | $1,380,927.16 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 6 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,864 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $140.02 to $141.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 14,854 | $86.63 | $1,286,802.02 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 5 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 651 | $142.15 | $92,540.30 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 4 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,833 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $142.09 to $142.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 2,565 | $141.36 | $362,590.97 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,484 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $141.03 to $142.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 6,821 | $140.60 | $959,046.24 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,049 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $140.02 to $141.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 10,037 | $103.57 | $1,039,532.09 |
DisclosureSEC source: 0001022079-22-000104 · wf-form4_165359711860113.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 156,282 | $86.63 Strike: $86.63 | $13,538,709.66 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · derivative · entry 16 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,854 Underlying: Common Stock · 156,282 shares Expires 2029-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 126,126 | $103.57 Strike: $103.57 | $13,062,869.82 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · derivative · entry 15 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,037 Underlying: Common Stock · 126,126 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F10 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 156,282 | $140.12 | $21,898,546.40 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 12 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,833 F9 · price: This transaction was executed in multiple trades at prices ranging from $140.00 to $140.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 156,282 | $86.63 | $13,538,709.66 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 11 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 126,126 | $140.12 | $17,672,775.12 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 10 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,833 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F8 · price: This transaction was executed in multiple trades at prices ranging from $140.00 to $140.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 126,126 | $103.57 | $13,062,869.82 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 9 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 42,568 | $86.63 Strike: $86.63 | $3,687,665.84 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · derivative · entry 14 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,136 Underlying: Common Stock · 42,568 shares Expires 2029-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F11 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 34,898 | $103.57 Strike: $103.57 | $3,614,385.86 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · derivative · entry 13 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,163 Underlying: Common Stock · 34,898 shares Expires 2028-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F10 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 300 | $142.24 | $42,672.00 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 8 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,833 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F7 · price: This transaction was executed in multiple trades at prices ranging from $142.21 to $142.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,000 | $141.51 | $141,509.00 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 7 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,133 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F6 · price: This transaction was executed in multiple trades at prices ranging from $141.11 to $141.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 41,268 | $140.12 | $5,782,430.89 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 6 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,133 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $140.00 to $140.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 42,568 | $86.63 | $3,687,665.84 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 5 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 200 | $142.26 | $28,451.00 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 4 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,833 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $142.22 to $142.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 800 | $141.54 | $113,233.60 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 3 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,033 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $141.11 to $141.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 33,898 | $140.12 | $4,749,923.35 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,833 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $140.00 to $140.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 34,898 | $103.57 | $3,614,385.86 |
DisclosureSEC source: 0001022079-22-000102 · wf-form4_165351065441914.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 22, 2022. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:53 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 32,570 | $130.09 | $4,237,031.30 |
DisclosureSEC source: 0001022079-22-000062 · wf-form4_164686279064545.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,833 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:53 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 70,184 | $130.09 | $9,130,236.56 |
DisclosureSEC source: 0001022079-22-000062 · wf-form4_164686279064545.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,403 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 00:53 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 109,317 | $0.00 Strike: $127.73 | $0.00 |
DisclosureSEC source: 0001022079-22-000041 · wf-form4_164609595731029.xml · derivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,317 Underlying: Common Stock · 109,317 shares Expires 2032-02-24 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 00:53 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 22,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-22-000041 · wf-form4_164609595731029.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,219 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 00:16 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,255 | $130.23 | $293,668.65 |
DisclosureSEC source: 0001022079-22-000023 · wf-form4_164583456974219.xml · nonDerivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,709 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 00:16 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 7,463 | $130.09 | $970,861.67 |
DisclosureSEC source: 0001022079-22-000023 · wf-form4_164583456974219.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,964 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 20:16 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 4,193 | $95.80 Strike: $95.80 | $401,668.44 |
DisclosureSEC source: 0001022079-21-000117 · wf-form4_162767612798957.xml · derivative · entry 9 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,193 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on April 28, 2021. F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 21, 2018, the second on February 21, 2019 and the final on February 21, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.